Vicore Pharma Holding AB (publ)

OM:VICO Stock Report

Market Cap: SEK 1.8b

Vicore Pharma Holding Balance Sheet Health

Financial Health criteria checks 6/6

Vicore Pharma Holding has a total shareholder equity of SEK377.7M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK406.9M and SEK29.2M respectively.

Key information

0%

Debt to equity ratio

SEK 0

Debt

Interest coverage ration/a
CashSEK 380.42m
EquitySEK 377.74m
Total liabilitiesSEK 29.17m
Total assetsSEK 406.90m

Recent financial health updates

We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate

Sep 11
We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate

Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

Feb 10
Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Sep 21
We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

May 25
We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Nov 13
Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Jul 26
Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Recent updates

We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate

Sep 11
We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate

Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

Feb 10
Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Sep 21
We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

May 25
We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)

Jan 10
Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)

Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Nov 13
Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Jul 26
Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?

Mar 03
Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?

What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition

Jan 11
What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition

Financial Position Analysis

Short Term Liabilities: VICO's short term assets (SEK406.9M) exceed its short term liabilities (SEK28.5M).

Long Term Liabilities: VICO's short term assets (SEK406.9M) exceed its long term liabilities (SEK646.0K).

Debt to Equity History and Analysis

Debt Level: VICO is debt free.

Reducing Debt: VICO had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VICO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VICO has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 22.2% each year.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:09
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vicore Pharma Holding AB (publ) is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hanseung YooBryan Garnier & Co
Oscar Haffen LammBryan Garnier & Co
Patrik LingDNB Markets